Potent and selective inhibitor of CDKs. More potent than olomoucine. Inhibits CDK1/cyclin B kinase (IC50 = 450 nM), CDK2 (IC50 = 700 nM) and CDK5/p35 (IC50 = 160 nM). Inhibits M phase promoting factor (MPF) kinase activity. Arrests human fibroblasts in G1 phase. Antitumor compound. Activates the mitogen-activated protein kinase pathway. Targets both the p53 and NF-kappaB pathways[10]. Has effects on calcium channel gating. Prevents DNA damage-induced cyclin A1 upregulation. Apoptosis inducer. As CYC202 in phase I clinical trials. Reviews.

Price Not Available 50 mg (R)-Roscovitine Supplier Page
Catalog Number AG-CR1-0006-M050
Alternative Name(s) 6-Benzylamino-2-(R)-[(1-ethyl)-2-hydroxyethylamino]-9-isopropylpurine
Research Area Biochemicals, Cancer
Molecular Formula C19H26N6O
CAS# 186692-46-6
Purity >98%
Inchi InChI=1S/C19H26N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,12-13,15,26H,4,10-11H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1
Size 50 mg
Supplier Page http://www.adipogen.com/ag-cr1-0006/-r-roscovitine.html